PharmX Technologies Yönetim

Yönetim kriter kontrolleri 3/4

Şu anda CEO hakkında yeterli bilgiye sahip değiliz.

Anahtar bilgiler

Tom Culver

İcra Kurulu Başkanı

AU$219.3k

Toplam tazminat

CEO maaş yüzdesi	87.3%
CEO görev süresi	less than a year
CEO sahipliği	n/a
Yönetim ortalama görev süresi	3.3yrs
Yönetim Kurulu ortalama görev süresi	4.4yrs

Son yönetim güncellemeleri

Recent updates

At AU$0.089, Is It Time To Put Corum Group Limited (ASX:COO) On Your Watch List?

Apr 29

Corum Group (ASX:COO) Is Posting Healthy Earnings, But It Is Not All Good News

Mar 02

Corum Group Limited (ASX:COO) Is Going Strong But Fundamentals Appear To Be Mixed : Is There A Clear Direction For The Stock?

Dec 13

CEO Tazminat Analizi

Tom Culver'un ücretlendirmesi PharmX Technologies'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Jun 30 2024	AU$219k	AU$191k	AU$95k

Tazminat ve Piyasa: Tom 'nin toplam tazminatı ($USD 142.50K ), Australian pazarındaki benzer büyüklükteki şirketler için ortalamanın altındadır ($USD 297.90K ).

Tazminat ve Kazançlar: Tom şirketinin tazminatını şirket performansıyla karşılaştırmak için yeterli veri yok.

CEO

Tom Culver

less than a year

Görev süresi

AU$219,292

Tazminat

Mr. Tom Culver serves as Head of Wealth & Crypto Services at Douugh Limited since January 2021. Mr. Culver is Goodments Founder & CEO. Mr. Culver is Chief Executive Officer of PharmX Technologies Limited f...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Tom Culver	Chief Executive Officer	less than a year	AU$219.29k	Veri yok
Zoe Hillier	Chief Financial Officer	3.3yrs	AU$276.23k	0.10% A$ 43.1k
James Nevile	Chief Operating Officer	3.3yrs	AU$310.49k	0% A$ 0
Sally McDow	Company Secretary	no data	Veri yok	Veri yok

3.3yrs

Ortalama Görev Süresi

Deneyimli Yönetim: PHX 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 3.3 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Jayne Shaw	Independent Non-Executive Director	4.1yrs	AU$97.68k	0.46% A$ 191.9k
Andrew Jonathan Newbery	Non-Executive Director	4.8yrs	AU$185.37k	0.29% A$ 118.2k
Philip England	Non-Executive Chairman	5yrs	AU$324.28k	4.51% A$ 1.9m
Alexander Mellis	Non-Executive Independent Director	less than a year	Veri yok	Veri yok

4.4yrs

Ortalama Görev Süresi

Deneyimli Yönetim Kurulu: PHX 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 4.4 yıldır).

PharmX Technologies Yönetim

Yönetim kriter kontrolleri 3/4

Anahtar bilgiler

Son yönetim güncellemeleri

PharmX Technologies Limited Announces Change of Company Secretary

PharmX Technologies Limited, Annual General Meeting, Nov 26, 2024

PharmX Technologies Limited Appoints Alexander Mellis as A Non-Executive and Independent Alternate Director

PharmX Technologies Limited Announces the Appointment of Tom Culver as Chief Executive Officer, Effective 20 November 2023

PharmX Technologies Limited Announces the Appointment of Tom Culver as Chief Executive Officer, Effective 20 November 2023

PharmX Technologies Limited, Annual General Meeting, Nov 21, 2023

Recent updates

PharmX Technologies Limited Announces Change of Company Secretary

PharmX Technologies Limited, Annual General Meeting, Nov 26, 2024

PharmX Technologies Limited Appoints Alexander Mellis as A Non-Executive and Independent Alternate Director

Full year 2024 earnings released: EPS: AU$0 (vs AU$0.001 loss in FY 2023)

New major risk - Share price stability

PharmX Technologies Limited to Report Fiscal Year 2024 Results on Aug 21, 2024

First half 2024 earnings released: EPS: AU$0 (vs AU$0.001 loss in 1H 2023)

PharmX Technologies Limited to Report First Half, 2024 Results on Feb 23, 2024

Now 27% overvalued

What Is PharmX Technologies Limited's (ASX:PHX) Share Price Doing?

New major risk - Market cap size

New minor risk - Share price stability

PharmX Technologies Limited Announces the Appointment of Tom Culver as Chief Executive Officer, Effective 20 November 2023

PharmX Technologies Limited Announces the Appointment of Tom Culver as Chief Executive Officer, Effective 20 November 2023

PharmX Technologies Limited, Annual General Meeting, Nov 21, 2023

New major risk - Revenue and earnings growth

Full year 2023 earnings released: AU$0.002 loss per share (vs AU$0 in FY 2022)

Corum Group Limited to Report Fiscal Year 2023 Results on Aug 23, 2023

Jonas Software AUS Pty Ltd entered into an agreement to acquire Corum Health Pty Ltd and Amfac Pty Ltd. from Corum Group Limited (ASX:COO) for AUD 6.3 million.

A Look At The Intrinsic Value Of Corum Group Limited (ASX:COO)

At AU$0.044, Is Corum Group Limited (ASX:COO) Worth Looking At Closely?

First half 2023 earnings released: AU$0.001 loss per share (vs AU$0 in 1H 2022)

No independent directors

Corum Group Limited, Annual General Meeting, Nov 14, 2022

Full year 2022 earnings released: EPS: AU$0 (vs AU$0.002 in FY 2021)

Corum Group Limited Launches Pharmxchange Platform

No independent directors

Zenith Payments Pty Ltd completed the acquisition Real Estate eCommerce business unit of Corum Group Limited from Corum Group Limited (ASX:COO).

First half 2022 earnings: EPS and revenues miss analyst expectations

Corum Group Limited to Report First Half, 2022 Results on Feb 10, 2022

Corum Group Limited Announces Resignation of Julian Sallabank as Managing Director

Zenith Payments Pty Ltd agreed to acquire Real Estate eCommerce business unit of Corum Group Limited from Corum Group Limited (ASX:COO) for AUD 0.5 million.

Is Now The Time To Put Corum Group (ASX:COO) On Your Watchlist?

Full year 2021 earnings released: EPS AU$0.002 (vs AU$0.001 in FY 2020)

At AU$0.089, Is It Time To Put Corum Group Limited (ASX:COO) On Your Watch List?

Corum Group (ASX:COO) Is Posting Healthy Earnings, But It Is Not All Good News

First half 2021 earnings released: EPS AU$0.002 (vs AU$0.001 loss in 1H 2020)

Corum Group Limited to Report First Half, 2021 Results on Feb 24, 2021

Corum Group Limited (ASX:COO) Is Going Strong But Fundamentals Appear To Be Mixed : Is There A Clear Direction For The Stock?

Corum Group Limited Announces Appointment of Dennis Bastas to the Board of Directors

Corum Group Limited Appoints Eryl Baron as Company Secretary, Effective 3 November 2020

Corum Group Limited Appoints Jayne Shaw to its Board of Directors

Corum Group Limited (ASX:COO) completed the acquisition of remaining 57% stake in PharmX Pty Ltd from Mountaintop Systems Pty. Ltd. and Daleflag Pty Ltd.

Corum Group Limited (ASX:COO) entered into a binding agreement to acquire remaining 57% stake in PharmX Pty Ltd from Mountaintop Systems Pty Ltd and Daleflag Pty Ltd for AUD 7.9 million

Corum Group Limited (ASX:COO) completed the acquisition of an unknown additional minority stake in PharmX Pty Limited from Fred IT Group Pty Ltd.

CEO Tazminat Analizi

CEO

Görev süresi

Tazminat

Liderlik Ekibi

Ortalama Görev Süresi

Yönetim Kurulu Üyeleri

Ortalama Görev Süresi